Clinical Impact of Sarcopenia and Inflammatory/Nutritional Markers in Patients with Unresectable Metastatic Urothelial Carcinoma Treated with Pembrolizumab
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Clinical Impact of Sarcopenia and Inflammatory/Nutritional Markers in Patients with Unresectable Metastatic Urothelial Carcinoma Treated with Pembrolizumab
Authors
Keywords
-
Journal
Diagnostics
Volume 10, Issue 5, Pages 310
Publisher
MDPI AG
Online
2020-05-18
DOI
10.3390/diagnostics10050310
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Preoperative predictive factors focused on inflammation-, nutrition-, and muscle-status in patients with upper urinary tract urothelial carcinoma undergoing nephroureterectomy
- (2019) Yoshitaka Itami et al. International Journal of Clinical Oncology
- Evaluation of Preoperative Abdominal Adipose Tissue–, Inflammation-, Muscle Mass–, and Nutritional Status–based Prognostic Markers to Assess Renal Dysfunction in Living Kidney Donors
- (2019) Shunta Hori et al. TRANSPLANTATION PROCEEDINGS
- Prognostic impact of the Controlling Nutritional Status score in patients with non-small cell lung cancer treated with pembrolizumab
- (2019) Taro Ohba et al. Journal of Thoracic Disease
- Blood Immune Cell Biomarkers in Patient With Lung Cancer Undergoing Treatment With Checkpoint Blockade
- (2019) Miriam Möller et al. JOURNAL OF IMMUNOTHERAPY
- Pretreatment prognostic nutritional index as a novel biomarker in non-small cell lung cancer patients treated with immune checkpoint inhibitors
- (2019) Fumihiro Shoji et al. LUNG CANCER
- Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors
- (2019) Satya Das et al. Journal for ImmunoTherapy of Cancer
- Clinical Characteristics of Liver Metastasis in Nivolumab-treated Patients with Non-small Cell Lung Cancer
- (2018) TAKAYUKI SHIROYAMA et al. ANTICANCER RESEARCH
- Sarcopenic overweight is associated with early acute limiting toxicity of anti-PD1 checkpoint inhibitors in melanoma patients
- (2017) Valentine Heidelberger et al. INVESTIGATIONAL NEW DRUGS
- Avelumab, an Anti–Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study
- (2017) Andrea B. Apolo et al. JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
- (2017) Michael J Overman et al. LANCET ONCOLOGY
- Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b study
- (2017) Elizabeth R Plimack et al. LANCET ONCOLOGY
- Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial
- (2017) Padmanee Sharma et al. LANCET ONCOLOGY
- Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer
- (2017) Stephen J. Bagley et al. LUNG CANCER
- Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
- (2017) Joaquim Bellmunt et al. NEW ENGLAND JOURNAL OF MEDICINE
- Integrative Assessment of Pretreatment Inflammation-, Nutrition-, and Muscle-Based Prognostic Markers in Patients with Muscle-Invasive Bladder Cancer Undergoing Radical Cystectomy
- (2017) Makito Miyake et al. ONCOLOGY
- Prognostic value of sarcopenia in adults with solid tumours: A meta-analysis and systematic review
- (2016) Shlomit Strulov Shachar et al. EUROPEAN JOURNAL OF CANCER
- Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
- (2016) Jonathan E Rosenberg et al. LANCET
- Predictive biomarkers for checkpoint inhibitor-based immunotherapy
- (2016) Geoffrey T Gibney et al. LANCET ONCOLOGY
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
- (2016) Martin Reck et al. NEW ENGLAND JOURNAL OF MEDICINE
- Proposal for new diagnostic criteria for low skeletal muscle mass based on computed tomography imaging in Asian adults
- (2016) Yuhei Hamaguchi et al. NUTRITION
- Nivolumab in Previously Untreated Melanoma without BRAF Mutation
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
- (2015) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Prognostic Role of Platelet to Lymphocyte Ratio in Solid Tumors: A Systematic Review and Meta-Analysis
- (2014) A. J. Templeton et al. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
- The systemic inflammation-based neutrophil–lymphocyte ratio: Experience in patients with cancer
- (2013) Graeme J.K. Guthrie et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
- Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study
- (2008) Carla MM Prado et al. LANCET ONCOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started